Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 228,724 | 125,449 | 156,366 | 151,087 | 128,198 |
| Depreciation Amortization | 161,779 | 131,159 | 126,658 | 94,881 | 98,170 |
| Income taxes - deferred | -9,702 | 28,254 | 1,945 | 2,689 | 7,060 |
| Accounts receivable | -21,196 | -48,279 | -52,780 | -16,963 | -28,088 |
| Accounts payable and accrued liabilities | -12,732 | 34 | 22,076 | 1,174 | 4,599 |
| Other Working Capital | 14,814 | 5,943 | -13,494 | 28,216 | -3,774 |
| Other Operating Activity | 79,453 | 75,514 | 76,128 | 45,749 | 45,967 |
| Operating Cash Flow | $441,140 | $318,074 | $316,899 | $306,833 | $252,132 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -25,125 | -46,217 | -40,248 | N/A | N/A |
| PPE Investments | -140,054 | -82,431 | -55,288 | -63,252 | -56,925 |
| Net Acquisitions | -824,868 | 47,450 | -648,482 | -247,651 | -234,267 |
| Purchase Of Investment | N/A | N/A | N/A | -34,235 | -26,648 |
| Sale Of Investment | 35,849 | 9,128 | 47,652 | 19,743 | 21,000 |
| Other Investing Activity | -805 | -516 | 3,694 | -2,221 | -1,150 |
| Investing Cash Flow | $-955,003 | $-72,586 | $-692,672 | $-327,616 | $-297,990 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 2,755,028 | 236,856 | 1,044,666 | 492,514 | 298,920 |
| Debt Repayment | -2,201,003 | -372,435 | -656,636 | -417,331 | -194,536 |
| Common Stock Issued | 37,657 | 38,870 | 23,197 | 39,367 | 73,688 |
| Common Stock Repurchased | -13,846 | -106,909 | -12,267 | -117,478 | -122,018 |
| Other Financing Activity | -19,777 | -4,858 | -18,204 | -4,330 | 5,360 |
| Financing Cash Flow | $558,059 | $-208,476 | $380,756 | $-7,258 | $61,414 |
| Exchange Rate Effect | -9,474 | 11,234 | -2,996 | -12,695 | -10,379 |
| Beginning Cash Position | 166,331 | 119,894 | 119,963 | 162,575 | 155,927 |
| End Cash Position | 197,318 | 166,331 | 119,894 | 119,963 | 160,023 |
| Net Cash Flow | $30,987 | $46,437 | $-69 | $-42,612 | $4,096 |
| Free Cash Flow | |||||
| Operating Cash Flow | 441,140 | 318,074 | 316,899 | 306,833 | 252,132 |
| Capital Expenditure | -140,054 | -82,431 | -55,288 | -63,252 | -56,925 |
| Free Cash Flow | 301,086 | 235,643 | 261,611 | 243,581 | 195,207 |